Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros

News provided by

Oct 21, 2013, 08:00 ET

NEW YORK, October 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Seattle Genetics Inc. (NASDAQ: SGEN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Insmed Incorporated (NASDAQ: INSM), and Omeros Corporation (NASDAQ: OMER). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Arena Pharmaceuticals, Inc. Research Report

On October 15, 2013, Arena Pharmaceuticals, Inc. (Arena) reported that Eisai Inc. will increase its BELVIQ^® (a drug approved by the US Food and Drug Administration for chronic weight management) sales-force to approximately 400 representatives by December 2013. The Company stated that Eisai Inc. is responsible for the marketing and distribution of BELVIQ in the United States under its agreement with Arena. According to Arena, this move will double the size of the sales-force from when BELVIQ became available in June 2013 and enable Eisai to reach approximately 65,000 physicians in the US, including primary care providers, endocrinologists, cardiovascular specialists, and gastrointestinal specialists. Jack Lief, Arena's President and CEO, stated, "We have seen increasing physician interest in BELVIQ as an important treatment option for chronic weight management, the payor landscape has improved and we are encouraged by the early response to the patient support programs and recently launched patient campaign. Eisai's efforts have led to month over month increases in BELVIQ prescriptions to date, and we expect that the expansion of the BELVIQ sales force will help communicate the safety and efficacy of BELVIQ to an increased number of physicians." The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/6a95_ARNA]

Seattle Genetics Inc. Research Report

On October 15, 2013, Seattle Genetics Inc. (Seattle Genetics) announced that it will report its financial results for Q3 2013 after the markets close on Tuesday, November 5, 2013. Seattle Genetics reported that it will hold its Q3 2013 conference call and webcast on the same day at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide a general corporate update. Also, the live webcast and its replay will be available on the Company's website through the Investors and News section. The Full Research Report on Seattle Genetics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ff98_SGEN]

Halozyme Therapeutics, Inc. Research Report

On October 15, 2013, Halozyme Therapeutics, Inc. (Halozyme) announced that the first patient has been dosed in a closed loop control ("artificial pancreas") clinical study involving the Company's recombinant human hyaluronidase. The Company informed that the study is being performed by researchers at Yale School of Medicine in patients with type 1 diabetes. According to Halozyme, the study will compare blood glucose control observed when using lispro (marketed as Humalog^®), a rapid acting analog insulin, alone versus using hyaluronidase in combination with lispro in two different administration formats. Commenting on the clinical study, Gregory I. Frost, Ph.D., President and CEO of Halozyme, stated, "We are pleased that Yale investigators received grant funding from JDRF to independently test our enzyme in this important research to advance insulin therapy for patients in need. We look forward to the results of this novel study." The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ea1b_HALO]

Insmed Incorporated Research Report

On October 15, 2013, Insmed Incorporated (Insmed) announced the completion of patient enrollment in its Phase 2 clinical study of ARIKACE^®, or liposomal amikacin for inhalation, for patients with recalcitrant nontuberculous mycobacterial (NTM) lung disease in the US and Canada. Insmed informed that ARIKACE has received Orphan Drug, Qualified Infectious Disease Product (QIDP), and Fast Track designations from the US Food and Drug Administration (FDA) for the treatment of NTM lung infections. Further, the Company announced that it has initiated the Scientific Advice Working Party (SAWP) process with the European Medicines Agency (EMA) and expects to have discussions with the EMA regarding ARIKACE for NTM lung disease during Q4 2013. Insmed stated that it is also in the process of evaluating other international markets, such as Japan, where NTM lung infections are already a growing unmet medical need. The Full Research Report on Insmed Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9c5b_INSM]

Omeros Corporation Research Report

On October 15, 2013, Omeros Corporation (Omeros) announced that the US Food and Drug Administration (FDA) has confirmed its agreement with the Pediatric Study Plan (PSP) proposed by Omeros to study the use of OMS302 in pediatric patients undergoing primary cataract extraction. Omeros informed that the FDA has issued a Written Request consistent with the PSP, meaning that successful completion of the PSP would make OMS302 eligible for an additional six months of marketing exclusivity in the US. Commenting on the development, Gregory A. Demopulos, M.D., Chairman and CEO of Omeros, stated, "With FDA's Written Request and agreement on our Pediatric Study Plan, we now have clear paths forward to obtain additional marketing exclusivity for our drug in both the U.S. and Europe. We look forward to making OMS302 available to ophthalmic surgeons and their patients in these major markets next year." The Full Research Report on Omeros Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e3c9_OMER]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner